Is mobocertinib Mobocertinib/Mobocertinib?

Mobocertinib is Mobocertinib/Mobocertinib, a drug used to treat non-small cell lung cancer (NSCLC) with EGFR gene mutations. This drug can interfere with the EGFR signaling pathway, thereby inhibiting the growth and division of cancer cells. Mobosetinib, also known as the "third-generation EGFR inhibitor", is specifically designed to selectively target lung cancer treatment with EGFR Exon20 insertion mutations. It is also known as Exkivity (trade name).

Mobocertinibis a targeted drug called a tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins that cells use to signal each other to grow. They act as chemical messengers. Blocking these signals can help slow or stop the development of cancer. There are several different tyrosine kinases. Before receiving treatment, patients need to have their cancer cells tested. The test looks for changes in these proteins or genes. They used moboxetinib to look for changes in the EGFR gene.

Mobosetinib The original drug has been launched in China, but it is not included in the medical insurance. The price of the common specification 40mg*112 pills per box is about 40,000 yuan, which is very high. The Hong Kong clinical version specification 40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.